Earnings Preview: Zymeworks Inc. (ZYME) Q2 Earnings Expected to DeclineZacks Investment Research • 07/28/21
Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and ChemotherapyBusiness Wire • 07/28/21
5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021The Motley Fool • 07/23/21
Earnings Preview: Zymeworks Inc. (ZYME) Q1 Earnings Expected to DeclineZacks Investment Research • 04/29/21
Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual MeetingBusiness Wire • 04/10/21
BlackBerry, Lam Research, Shopify, Square, Zoom and More Wednesday Afternoon Analyst Calls24/7 Wall Street • 03/31/21
Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021Business Wire • 03/10/21
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/22/21
Zymeworks Plummets As Cancer Drug Falls Short Of 'Tempered' ExpectationsInvestors Business Daily • 01/28/21
Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical DevelopmentBusiness Wire • 01/27/21
Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers SymposiumBusiness Wire • 01/15/21
Zymeworks to Present at J.P. Morgan Healthcare Conference and Host Two Webcasts in January to Provide Updates on its Lead Clinical Programs Zanidatamab and ZW49Business Wire • 01/07/21